title: Exploring the nicotinic acetylcholine receptor-associated proteome with iTRAQ and transgenic mice.
abstract: Neuronal nicotinic acetylcholine receptors (nAChRs) containing α4 and β2 subunits are the principal receptors in the mammalian central nervous system that bind nicotine with high affinity. These nAChRs are involved in nicotine dependence, mood disorders, neurodegeneration and neuroprotection. However, our understanding of the interactions between α4β2-containing (α4β2(∗)) nAChRs and other proteins remains limited. In this study, we identified proteins that interact with α4β2(∗) nAChRs in a genedose dependent pattern by immunopurifying β2(∗) nAChRs from mice that differ in α4 and β2 subunit expression and performing proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ). Reduced expression of either the α4 or the β2 subunit results in a correlated decline in the expression of a number of putative interacting proteins. We identified 208 proteins co-immunoprecipitated with these nAChRs. Furthermore, stratified linear regression analysis indicated that levels of 17 proteins was correlated significantly with expression of α4β2 nAChRs, including proteins involved in cytoskeletal rearrangement and calcium signaling. These findings represent the first application of quantitative proteomics to produce a β2(∗) nAChR interactome and describe a novel technique used to discover potential targets for pharmacological manipulation of α4β2 nAChRs and their downstream signaling mechanisms.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA.
authors.forename: Tristan D
authors.initials: TD
authors.lastname: McClure-Begley
authors.forename: Kathy L
authors.initials: KL
authors.lastname: Stone
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Marks
authors.forename: Sharon R
authors.initials: SR
authors.lastname: Grady
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Colangelo
authors.forename: Jon M
authors.initials: JM
authors.lastname: Lindstrom
authors.forename: Marina R
authors.initials: MR
authors.lastname: Picciotto
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism; D002853:Chromatography, Liquid; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009538:Nicotine / Q000494:pharmacology; D011485:Protein Binding; D020543:Proteome / Q000032:analysis* / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism*; D053719:Tandem Mass Spectrometry
chemical_list: D020543:Proteome; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; D009538:Nicotine
keywords: Affinity purification; Nicotinic receptor; Quantitative proteomics; Transgenic mouse
references.citation: Mol Cell Neurosci. 2009 Feb;40(2):280-92
references.pmid: 19063970
references.citation: J Proteome Res. 2006 Mar;5(3):651-8
references.pmid: 16512681
references.citation: Epilepsia. 2012 Jun;53 Suppl 1:45-52
references.pmid: 22612808
references.citation: J Pharmacol Exp Ther. 2009 Aug;330(2):541-9
references.pmid: 19435931
references.citation: Trends Pharmacol Sci. 2010 Dec;31(12):580-6
references.pmid: 20965579
references.citation: Nucleic Acids Res. 2012 Jan;40(Database issue):D71-5
references.pmid: 22102590
references.citation: J Neurol Sci. 2004 Oct 15;225(1-2):39-49
references.pmid: 15465084
references.citation: J Pharmacol Exp Ther. 2009 Jul;330(1):152-61
references.pmid: 19336664
references.citation: Neuroscience. 2009 Feb 18;158(4):1311-25
references.pmid: 19101612
references.citation: Nucleic Acids Res. 2003 Jan 1;31(1):334-41
references.pmid: 12520017
references.citation: Trends Neurosci. 2005 Jul;28(7):343-5
references.pmid: 15979499
references.citation: J Neurosci. 2012 Jun 13;32(24):8391-400
references.pmid: 22699919
references.citation: Mol Cell Proteomics. 2007 Sep;6(9):1638-55
references.pmid: 17533153
references.citation: Neuropharmacology. 2004;47 Suppl 1:148-66
references.pmid: 15464134
references.citation: Eur J Pharmacol. 2005 May 9;514(2-3):83-90
references.pmid: 15878498
references.citation: J Proteome Res. 2007 Oct;6(10):4019-24
references.pmid: 17867667
references.citation: J Proteome Res. 2010 Aug 6;9(8):4152-60
references.pmid: 20578722
references.citation: J Pharmacol Exp Ther. 2011 Apr;337(1):187-200
references.pmid: 21228066
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):244-9
references.pmid: 17041007
references.citation: J Neurosci. 1993 Apr;13(4):1551-68
references.pmid: 8463835
references.citation: Dev Neurobiol. 2011 Sep;71(9):747-58
references.pmid: 21557512
references.citation: J Mol Neurosci. 2006;30(1-2):97-8
references.pmid: 17192645
references.citation: Mol Neurobiol. 2008 Aug;38(1):101-21
references.pmid: 18690555
references.citation: Nat Methods. 2006 Dec;3(12):981-3
references.pmid: 17072306
references.citation: Prog Brain Res. 2006;158:41-82
references.pmid: 17027691
references.citation: Eur J Pharmacol. 2013 Feb 15;701(1-3):1-6
references.pmid: 23313759
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20570-5
references.pmid: 18077321
references.citation: J Pharmacol Exp Ther. 2012 Aug;342(2):245-54
references.pmid: 22532626
references.citation: J Neurosci. 2000 Sep 1;20(17):6431-41
references.pmid: 10964949
references.citation: J Neurosci. 1988 Sep;8(9):3395-404
references.pmid: 3171681
references.citation: Neuropharmacology. 2009 Jan;56(1):237-46
references.pmid: 18723036
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006103
references.pmid: 17253581
references.citation: Genome Res. 2009 Feb;19(2):284-93
references.pmid: 19015324
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1247-52
references.pmid: 17850767
references.citation: Trends Pharmacol Sci. 2010 Oct;31(10):455-62
references.pmid: 20674046
references.citation: Stat Biosci. 2009 Nov;1(2):228-245
references.pmid: 21927625
references.citation: Nat Rev Neurosci. 2012 Feb 15;13(3):169-82
references.pmid: 22334212
references.citation: Mol Pharmacol. 1999 Mar;55(3):432-43
references.pmid: 10051526
references.citation: Mol Pharmacol. 2008 Jun;73(6):1796-807
references.pmid: 18337473
references.citation: Pharmacol Rev. 2011 Dec;63(4):938-66
references.pmid: 21969327
references.citation: J Neurosci. 2012 Apr 11;32(15):5177-85
references.pmid: 22496563
references.citation: Nature. 1995 Mar 2;374(6517):65-7
references.pmid: 7870173
references.citation: J Neurosci Res. 2006 May 1;83(6):929-43
references.pmid: 16511857
references.citation: J Neurosci. 1998 Jun 15;18(12):4461-72
references.pmid: 9614223
references.citation: J Neurochem. 2006 Aug;98(3):876-85
references.pmid: 16787419
references.citation: Genes Brain Behav. 2006 Mar;5(2):200-4
references.pmid: 16507010
references.citation: J Pharmacol Sci. 2011;116(1):6-17
references.pmid: 21498956
references.citation: Genes Cells. 2010 Jun;15(7):737-47
references.pmid: 20545768
references.citation: Mol Pharmacol. 1997 Dec;52(6):1105-12
references.pmid: 9415721
references.citation: J Proteome Res. 2008 Aug;7(8):3091-101
references.pmid: 18578521
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):703-11
references.pmid: 19481063
references.citation: J Comp Neurol. 2006 Dec 20;499(6):1016-38
references.pmid: 17072836
references.citation: J Neurosci. 2010 Sep 15;30(37):12455-65
references.pmid: 20844140